醋酸钙/碳酸镁(Calcium Acetate/Magnesium Carbonate) - 药物靶点：Phosphates_在研适应症：高磷血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Calcium citrate/Magnesium carbonate、OsvaRen、Rephoren

靶点

Phosphates

作用方式

调节剂

作用机制

Phosphates 调节剂(磷酸盐调节剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Fresenius Medical Care Zion LLC

Fresenius Kabi AG

非在研机构

Fresenius Medical Care Deutschland GmbH

最高研发阶段批准上市

首次获批日期

德国 (2006-07-01),

高磷血症

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C6H12CaMg2O10

InChIKeyBAWGBFZDYGEMLQ-UHFFFAOYSA-N

CAS号1173882-48-8

关联

2

项与醋酸钙/碳酸镁相关的临床试验

NCT02027662

/ Completed临床2/3期

Study to Investigate Efficacy and Safety Equivalence of OsvaRen® Tablets and OsvaRen® Granules

Phosphate binders are crucial to the control of elevated phosphate levels in patients with chronic kidney disease. With the new formulation of granules the pill burden of patients is sought to be reduced.
This study is about efficacy and safety of the new drug formulation and compares it to the "old" formulation which are film-coated tablets.

开始日期2014-01-01

申办/合作机构

Fresenius Medical Care Deutschland GmbH

EUCTR2012-004178-24-DE

/ Not yet recruitingN/A

Study to investigate the therapeutic equivalence of OsvaRen® tablets and OsvaRen® granules - OsvaRen NEW

开始日期2013-12-27

申办/合作机构

Fresenius Medical Care Deutschland GmbH

100 项与醋酸钙/碳酸镁相关的临床结果

登录后查看更多信息

100 项与醋酸钙/碳酸镁相关的转化医学

登录后查看更多信息

100 项与醋酸钙/碳酸镁相关的专利（医药）

登录后查看更多信息

10

项与醋酸钙/碳酸镁相关的文献（医药）

2021-03-01·Waste management (New York, N.Y.)1区 · 环境科学与生态学

Dried sludge reburning blended with calcium magnesium acetate addition in a fluidized bed combustor

1区 · 环境科学与生态学

Article

作者: Li, Zhi ; Zhang, Li-Hui ; Duan, Feng ; Yang, Shou-Meng

The combustion and pollutant emission characteristics of the dried sludge in a fluidized bed combustor (FBC) were studied. The sludge reburning technology was employed for the first time in FBC. A scheme for using the dried sludge reburning blended with calcium magnesium acetate (CMA) to reduce pollutants simultaneously was also proposed, and the effect of the CMA addition was investigated. Results showed that fluidized bed reburning technology can be used to effectively treat the sewage sludge with lower calorific values. As the secondary fuel mass percentage increases, the unburned carbon content in fly ash and the CO emission increase, resulting in lower combustion efficiency. However, the de-NO ratio increases from 37.1% to 53.7%, and the de-SO₂ ratio only increased from 1.6% to 7.6% as the secondary fuel mass percentage increase from 10% of 25%. For dried sludge blended with CMA, the minimum emissions of SO₂ and NO significantly decrease to 254 mg/Nm³ and 70.9 mg/Nm³ at Ca/S ratio of 2, respectively. Results of main gaseous pollutant emissions from the sludge combustion in an FBC using different pollutant removal methods were compared under well-defined conditions. Fuel reburning blended with CMA addition has the smallest SO₂ and NO emissions.

2019-02-01·Journal of nephrology3区 · 医学

Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study

3区 · 医学

Article

作者: Moe, Orson W ; Pasch, Andreas ; Pak, Charles Y C ; Sakhaee, Khashayar ; Quiñones, Henry ; Hamdi, Tamim

AIMS:

Cardiovascular (CV) complications are common in chronic kidney disease (CKD). Numerous metabolic disturbances including hyperphosphatemia, high circulating calciprotein particles (CPP), hyperparathyroidism, metabolic acidosis, and magnesium deficiency are associated with, and likely pathogenic for CV complications in CKD. The goal of this feasibility study was to determine whether effervescent calcium magnesium citrate (EffCaMgCit) ameliorates the aforementioned pathogenic intermediates.

METHODS:

Nine patients with Stage 3 and nine patients with Stage 5D CKD underwent a randomized crossover study, where they took EffCaMgCit three times daily for 7 days in one phase, and a conventional phosphorus binder calcium acetate (CaAc) three times daily for 7 days in the other phase. Two-hour postprandial blood samples were obtained on the day before and on the 7th day of treatment.

RESULTS:

In Stage 5D CKD, EffCaMgCit significantly increased T50 (half time for conversion of primary to secondary CPP) from baseline by 63% (P = 0.013), coincident with statistically non-significant declines in serum phosphorus by 25% and in saturation of octacalcium phosphate by 35%; CaAc did not change T50. In Stage 3 CKD, neither EffCaMgCit nor CaAc altered T50. With EffCaMgCit, a significant increase in plasma citrate was accompanied by statistically non-significant increase in serum Mg and phosphate. CaAc was without effect in any of these parameters in Stage 3 CKD. In both Stages 3 and 5D, both drugs significantly reduced serum parathyroid hormone. Only EffCaMgCit significantly increased serum bicarbonate by 3 mM (P = 0.015) in Stage 5D.

CONCLUSIONS:

In Stage 5D, EffCaMgCit inhibited formation of CPP, suppressed PTH, and conferred magnesium and alkali loads. These effects were unique, since they were not observed with CaAc. In Stage 3 CKD, neither of the regimens have any effect. These metabolic changes suggest that EffCaMgCit might be useful in protecting against cardiovascular complications of CKD by ameliorating pathobiologic intermediates.

2019-02-01·Nephrology (Carlton, Vic.)4区 · 医学

Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study

4区 · 医学

Article

作者: Schurgers, Leon J ; Vervloet, Marc G ; Neradova, Aegida ; Schumacher, Stefan P

ABSTRACT:

Aim:

Hyperphosphataemia is associated with increased mortality and morbidity in end stage renal disease. Despite phosphate binder therapy, a large proportion of patients do not reach the treatment target. In five contemporary binders we explored the influence of pH and phosphate concentration on phosphate binding. This interaction could be of relevance in clinical practice.

Methods:

Phosphate binding was quantified in vitro in 25 mL of purified water containing phosphate concentrations of 10, 15 and 20 mM and baseline pH values of 3.0 or 6.0, with a binder over 6 h. Lanthanum carbonate, calcium acetate/magnesium carbonate, sevelamer carbonate, calcium carbonate and sucroferric oxyhydroxide, 67 mg of each, were used. The experiments were performed in duplicate. The primary outcome was the difference in the amount of bound phosphate for each binder after 6 h in solutions at two different pH values. Secondary outcomes were the influence of phosphate concentration on phosphate binding, next to binding patterns and phosphate binder saturation.

Results and Conclusion:

In this specific in vitro setting, lanthanum carbonate, sevelamer carbonate, calcium carbonate and sucroferric oxyhydroxide bound more phosphate in the solution with baseline pH of 3.0. Differences however were small except for lanthanum carbonate. Calcium acetate/magnesium carbonate was most effective in a solution with baseline pH of 6.0. All phosphate binders bound more phosphate in solutions with higher concentrations of phosphate. Sevelamer carbonate, calcium acetate/magnesium carbonate and sucroferric oxyhydroxide bound most phosphate in the first hour and reached maximum binding capacity in less than 6 h.

100 项与醋酸钙/碳酸镁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	V03AE04	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高磷血症	德国	Fresenius Kabi AG	2006-07-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床3期	德国	Fresenius Medical Care Deutschland GmbH	2014-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2012	N/A	-	-	Mg salts (Mg carbonate and Ca acetate, Osvaren)	製餘顧醖製構製簾構範(構蓋鹹積遞製鬱糧窪醖) = 構願鬱壓艱艱觸齋鑰衊範鹹壓鹽齋窪鹽範鏇顧 (鹹艱齋膚淵齋餘遞遞憲 )	积极	2012-10-30
				Lanthane Carbonate (Fosrenol)	製餘顧醖製構製簾構範(構蓋鹹積遞製鬱糧窪醖) = 顧夢觸願網簾獵襯蓋餘範鹹壓鹽齋窪鹽範鏇顧 (鹹艱齋膚淵齋餘遞遞憲 )